Gateway 2012: Stäubli - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gateway 2012: Stäubli



Your online Gateway to Stäubli in 2012

www.staubli.us


About Stäubli

With presence in 25 countries, Stäubli is recognized worldwide for providing unrivaled quality and innovative technology. Since 1982, Stäubli has led the development of innovative solutions to improve productivity, safety, and product quality in robotics. Stäubli offers a comprehensive product range, including 4-axis SCARA and 6-axis robots for payloads of up to 250 kg. All robotic systems operate on the CS8 controller platform, which is perfectly adpated to robotics. Today, Stäubli Robotics is the leading-edge player in robotics around the world with its engineering as effective and dependable as its sales and services. Stäubli Robotics provides high performance, innovative and flexible solutions to satisfy the requirements of each industry. Designed to work in the most hostile environments as well as cleanrooms, Stäubli robots demonstrate their efficacy under all conditions.

New Products at Stäubli

The clean, precise and highly accurate range of Stericlean six axis robots provide the ideal solution to the unique set of requirements that automation in pharmaceutical, medical, and life sciences industries demand. Stericlean is the first fully VHP (Vapor Hydrogen Peroxide) resistant robot, providing fully automated operations in an isolator or cleanroom environment.

 

 

 



ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
23%
Oversee medical treatment of patients in the US.
14%
Provide treatment for patients globally.
7%
All of the above.
47%
No government involvement in patient treatment or drug development.
9%
Jim Miller Outsourcing Outlook Jim MillerOutside Looking In
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAdvances in Large-Scale Heterocyclic Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler New Era for Generic Drugs
Sean Milmo European Regulatory WatchSean MilmoTackling Drug Shortages
New Congress to Tackle Health Reform, Biomedical Innovation, Tax Policy
Combination Products Challenge Biopharma Manufacturers
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality

Click here